[taneq]

Is this the "new study" the article is referring to with "a single dose of psilocybin given to mice"? Oh. Some text. What's this?

> Eighty participants, ages 21 to 65, who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for major depressive disorder (MDD) will be stratified by study site and randomized with a 1-to-1 allocation under double-blind conditions to receive a single 25 mg oral dose of psilocybin or a single 100 mg oral dose of niacin. Niacin will serve as an active placebo.

I'm not convinced these participants are mice.

(As an aside, I love the way they talk about double blind conditions as if you're not going to be able to tell whether that pill was 25mg of psilocybin.).

[yarg]

It's possible to have a blind participant if they've not had psilocybin before and they are going to receive either psilocybin or one of a multitude of other psychoactive substances (at least that's how Johns Hopkins did it).